. home.aspx

NEWS

home.aspx
   


NICE knocks-back Janssen's Imbruvica in mantle cell lymphoma

September 28, 2017 / PharmaTimes reporter
SHARESHARESHARE

Janssen has received mixed news from the UK’s cost-effectiveness watchdog for its cancer drug Imbruvica (ibrutinib). In draft guidance NICE has declined to recommend Imbruvica’s use in England and Wales to treat mantle cell lymphoma.